JNJ — JOHNSON & JOHNSON

—
NYSE · Health Care · Pharmaceuticals · CIK 200406 ·
Last close
$278.70
Market Cap
$670.92B
52W High
$290.25
52W Low
$194.15
ADV30
7,687,925
Next earnings
2027-01-26

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 25,399,000,000 17,302,000,000 6,365,000,000 210,000,000 197,425,000,000 16,910,000,000 115,896,000,000
Jun 2026 25,310,000,000 17,259,000,000 7,174,000,000 5,534,000,000 201,061,000,000 20,422,000,000 116,090,000,000
Mar 2026 24,062,000,000 15,956,000,000 6,395,000,000 5,235,000,000 200,894,000,000 21,688,000,000 119,708,000,000
Dec 2025 24,564,000,000 16,596,000,000 5,591,000,000 5,116,000,000 199,210,000,000 19,709,000,000 117,666,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$27,608,000,000
Investing CF
$-7,177,000,000
Financing CF
$-18,543,000,000
CapEx
$-5,380,000,000
Dividends Paid
$-12,621,000,000
Buybacks
$-8,075,000,000
EPS Diluted TTM
$8.63
As of
2026-10-25

Balance + Analyst (yfinance extras)

Retained Earnings
—
Inventory
$15,144,000,000
Receivables
$19,046,000,000
ST Investments
$336,000,000
EBIT TTM
$26,208,000,000
Pretax Income TTM
$25,196,000,000
Interest Exp TTM
$1,012,000,000
Analysts
22

Yahoo Snapshot (yfinance, live)

Total Revenue
$99,334,995,968
EBITDA
$34,502,000,640
Free Cash Flow
$18,501,875,712
Enterprise Value
$662,495,494,144
Total Cash
$17,227,999,232
Total Debt
$44,650,999,808
Shares Out
2,407,310,266
Trailing EPS
$6.59
Book Value
$33.87
ROE
20.0%
ROA
8.5%
Div Yield
2.03%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 94,193,000,000 25,596,000,000 26,804,000,000 199,210,000,000 117,666,000,000 81,544,000,000 24,530,000,000
Dec 2024 88,821,000,000 21,249,000,000 14,066,000,000 180,104,000,000 108,614,000,000 71,490,000,000 24,266,000,000
Dec 2023 85,159,000,000 22,009,000,000 35,153,000,000 167,558,000,000 98,784,000,000 68,774,000,000 22,791,000,000
Dec 2022 79,990,000,000 21,013,000,000 17,941,000,000 187,378,000,000 110,574,000,000 76,804,000,000 21,194,000,000

TTM Snapshot

Revenues TTM
$97,929,000,000
NetIncome TTM
$21,037,000,000
OpCashFlow TTM
—
Assets (Latest)
$201,061,000,000
Forward EPS
$11.62

Max Pain — expiry 2026-11-27

max pain strike: $280.00 · spot: $272.70 · call oi: 3,240 · put oi: 5,263
Expected Move to 2026-11-27: ±$8.89 (3.26%) — implied range $263.81 – $281.59 · ATM straddle on $272.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ABBV AbbVie Inc. $517.59B $292.82 —
LLY ELI LILLY & Co $1.26T $1415.55 —
MRK Merck & Co., Inc. $353.44B $143.37 —
NVS NOVARTIS AG $302.46B $159.13 —
AZN ASTRAZENECA PLC $282.68B $182.27 —

News headlines (Yahoo Finance, 1h cache)

Global Multiport Surgical Robot Market 2026 Report: Trends and Forecast to 2030 | Capitalize on 19.1% CAGR as Intuitive Surgical, Medtronic, J&J and CMR Surgical Advance AI Surgery
2026-11-18 14:57 · Yahoo
Global Abdominal Surgical Robot Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 17.9% CAGR as Intuitive Surgical, Medtronic, J&J, and CMR Surgical Advance AI
2026-11-18 14:56 · Yahoo
Allergy Clinical Trial Services Global Market Report 2026: $1.66 Billion Forecast to 2030 | Capitalize on AI and Remote Trials with J&J, Merck, Sanofi, Novartis, and GSK
2026-11-18 14:35 · Yahoo
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
2026-11-17 23:47 · Yahoo
2 of the Best Dividend Stocks to Buy With $5,000 in November
2026-11-17 23:46 · Yahoo
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue
2026-11-17 18:50 · Yahoo
Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & Johnson
2026-11-17 17:14 · Yahoo
Johnson & Johnson's Planned Ollin Biosciences Acquisition to Serve as Growth Driver Past 2030, UBS Says
2026-11-17 16:35 · Yahoo
Guggenheim Names Top Biotech Stock Pick Following JNJ Latest Deal
2026-11-17 16:10 · Yahoo
J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts
2026-11-17 14:43 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.